Decision by Nice to rule out drug being available on NHS comes despite medicines licensing body giving green light
The UK’s health regulator has rejected a drug that can slow the progression of Alzheimer’s disease, saying its benefits are too small to justify the costs of the therapy and close monitoring of patients for signs of “serious side-effects”.
Lecanemab, which is given twice a month, removes sticky clumps of protein amyloid beta from the brain, believed to be a hallmark of the disease. The drug is not a cure. But in clinical trials, the therapy slowed cognitive decline by 27% in early Alzheimer’s patients, compared with a placebo.
About Author
More Stories
The anxiety secret: how the world’s leading life coach stopped living in fear
Male mosquitoes to be genetically engineered to poison females with semen in Australian research
My 90,000 shots of the sun: Andrew McCarthy’s best photograph